SAREPTA THERAPEUTICS, INC. (SRPT) Borrowing debt
- Total debt · latest quarter (USD): Value (m); Formula and calculation Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted). Period ending 2024-12-31..
- Net cash · latest quarter: Value (m); Formula and calculation Cash and cash equivalents plus current marketable securities less interest-bearing debt; negative net cash is displayed as net debt. Period ending 2024-12-31..
- Debt / assets · latest quarter: Value (m); Formula and calculation Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted) / total assets. Period ending 2024-12-31..
Borrowing debt
Overview →Financial period ending 2024-12-31; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Total debt · latest quarter (USD) | (m) | Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted). Period ending 2024-12-31. Calculation unavailable: missing inputs remain (m). |
| Net cash · latest quarter | (m) | Cash and cash equivalents plus current marketable securities less interest-bearing debt; negative net cash is displayed as net debt. Period ending 2024-12-31. Calculation unavailable: missing inputs remain (m). |
| Debt / assets · latest quarter | (m) | Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted) / total assets. Period ending 2024-12-31. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Borrowing debt due within one year | 0.00 USD | Long-term Debt, Current Maturities |
| Borrowing debt due after one year | (m) | Long-term Debt, Excluding Current Maturities |
| Commercial paper | (m) | |
| Cash and current securities | (m) | Cash and Cash Equivalents, at Carrying Value · Debt Securities, Available-for-sale, Current |
| Borrowing debt | (m) | Long-term Debt, Current Maturities · Long-term Debt, Excluding Current Maturities |
| Total assets | 3.96B USD | Assets |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Total debt | Net cash / debt | Borrowing debt due within one year (USD) | Borrowing debt due after one year (USD) | Commercial paper (USD) | Cash and current securities (USD) | Total assets (USD) | Debt / assets |
|---|---|---|---|---|---|---|---|---|
| 2024-12-31 | (m) | (m) | $0.00 | (m) | (m) | (m) | $3.96B | (m) |
| 2024-09-30 | (m) | (m) | $91.59M | (m) | (m) | (m) | $3.60B | (m) |
| 2024-06-30 | (m) | (m) | $91.50M | (m) | (m) | $1.46B | $3.42B | (m) |
| 2024-03-31 | (m) | (m) | $105.59M | (m) | (m) | $1.39B | $3.22B | (m) |
| 2023-12-31 | (m) | (m) | $105.48M | (m) | (m) | $1.68B | $3.26B | (m) |
| 2022-12-31 | (m) | (m) | $0.00 | (m) | (m) | $1.99B | $3.13B | (m) |
| 2015-03-31 | (m) | (m) | $99.00K | $1.45M | (m) | (m) | $242.71M | (m) |
| 2014-12-31 | (m) | (m) | $98.00K | $1.48M | (m) | (m) | $295.03M | (m) |
| 2014-09-30 | (m) | (m) | $97.00K | $1.50M | (m) | (m) | $319.06M | (m) |
| 2014-06-30 | (m) | (m) | $96.00K | $1.52M | (m) | (m) | $337.31M | (m) |
| 2014-03-31 | (m) | (m) | $94.00K | $1.55M | (m) | (m) | $275.39M | (m) |
| 2013-12-31 | (m) | (m) | $92.00K | $1.58M | (m) | (m) | $291.57M | (m) |
| 2013-09-30 | (m) | (m) | $91.00K | $1.60M | (m) | (m) | $304.48M | (m) |
| 2013-06-30 | (m) | (m) | $90.00K | $1.62M | (m) | (m) | $183.63M | (m) |
| 2013-03-31 | (m) | (m) | $90.00K | $1.65M | (m) | (m) | $193.34M | (m) |
| 2012-12-31 | (m) | (m) | $89.00K | $1.67M | (m) | (m) | $204.99M | (m) |
| 2012-09-30 | (m) | (m) | $88.00K | $1.69M | (m) | (m) | $53.08M | (m) |
| 2012-06-30 | (m) | (m) | $87.00K | $1.71M | (m) | (m) | $42.10M | (m) |
| 2012-03-31 | (m) | (m) | $86.00K | $1.74M | (m) | (m) | $46.65M | (m) |
| 2011-12-31 | (m) | (m) | $85.00K | $1.76M | (m) | (m) | $54.37M | (m) |
| 2011-09-30 | (m) | (m) | $84.00K | $1.78M | (m) | (m) | $61.08M | (m) |
| 2011-06-30 | (m) | (m) | $83.00K | $1.80M | (m) | (m) | $74.93M | (m) |
| 2010-12-31 | (m) | (m) | $81.00K | $1.84M | (m) | (m) | $45.98M | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |